Xu, J., Hu, H., Lu, M., Mao, C., Wang, W., Yang, J., Yin, F., Zhang, Y., Lin, X., Mi, Y., Liang, X., Li, Z., Zhang, J., Gu, K., Liu, Y., Wu, J. J. (2025). A phase 2 dose expansion study of ZG006, a trispecific T cell engager targeting CD3/DLL3/DLL3, as monotherapy in patients with advanced neuroendocrine carcinoma.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.e16341